OM1, Inc.

🇨🇦 Au revoir Montreal! We had a fun and productive week at ISPOR, connecting with new partners and learning about what's next for real-world evidence and machine learning. 💭 What themes or insights resonated with you at ISPOR? Tell us in the comments ⬇️ 🤝 ISPOR Annual 2025 has officially ended, but the insights don't stop there. Connect with us! https://okt.to/SUDo9d ISPOR—The Professional Society for Health Economics and Outcomes Research Rich Gliklich Richard Jenkins Kathryn Starzyk Joseph Zabinski, Ph.D., M.E.M. Jessica Probst Chandrasekar Gopalakrishnan, MD, MPH David Giannino Bradley Snipes Todd Price Maria Demko #ISPOR2025 #HEOR #AI #MachineLearning #RealWorldEvidence

Today's poster at ISPOR from Chandrasekar Gopalakrishnan, MD, MPH focused on: Predictors of Low Disease Activity/ Remission Amongst Rheumatoid Arthritis Patients Experiencing Inadequate Response to Biologic/ Targeted Synthetic Disease-Modifying Antirheumatic Drugs 💡 Why this matters In a population of difficult to treat patients, this study provides evidence on who is most likely to respond when switching to a new therapy. This identification of predictors of treatment response can inform personalized treatment strategies and shared decision-making. 📍Miss the poster session? There's still time to chat about these findings. Visit us at booth #1500. ISPOR—The Professional Society for Health Economics and Outcomes Research #ISPOR2025 #ISPORAnnual #RheumatoidArthritis #RWD #RealWorldEvidence #Pharmacovigilance

There's still time to meet the team at ISPOR! 📍Visit us at booth #1500 to see what makes OM1 a leader in multi-specialty real-world data, and why top life sciences organizations rely on us to drive impact at scale. ISPOR—The Professional Society for Health Economics and Outcomes Research Rich Gliklich Richard Jenkins Kathryn Starzyk Joseph Zabinski, Ph.D., M.E.M. Jessica Probst Chandrasekar Gopalakrishnan, MD, MPH David Giannino Bradley Snipes Todd Price Maria Demko #ISPOR2025 #HEOR #AI #MachineLearning #RealWorldEvidence

Today at ISPOR, Jessica Probst presented a poster on: Suicidal Ideation in Patients Treated With Glucagon-like Peptide 1 Receptor (GLP1) Agonists: A Retrospective Real-World Analysis 💡 Why this matters: Consistent with other findings and despite warnings on the label, there was no significant increase in SI prevalence after GLP-1 initiation. This is particularly relevant as it may influence prescribing patterns or induce patient or provider hesitancy regarding use of GLP-1s for weight loss in patients with certain risk factors such as a history of suicidality. 📍Miss the poster session? There's still time to chat about these findings. Visit us at booth #1500. ISPOR—The Professional Society for Health Economics and Outcomes Research #ISPOR2025 #ISPORAnnual #GLP1 #MentalHealth #RWD #RealWorldEvidence #AI #Pharmacovigilance

🇨🇦 Bonjour from Montreal! We're excited to connect with our fellow HEOR community and share real-world insights about suicidal ideation and GLP1 agonists, predictors of rheumatoid arthritis remission, and the latest in machine learning. Whether you're interested in evidence generation, patient-centered outcomes, or unlocking the power of AI-driven registries, let’s talk! https://okt.to/fI7MSo 👋 Stop by booth #1500, catch one of our poster sessions, or just say hi if you see us around. ISPOR—The Professional Society for Health Economics and Outcomes Research Rich Gliklich Richard Jenkins Kathryn Starzyk Joseph Zabinski, Ph.D., M.E.M. Jessica Probst Chandrasekar Gopalakrishnan, MD, MPH David Giannino Bradley Snipes Todd Price Maria Demko #ISPOR2025 #HEOR #AI #MachineLearning #RealWorldEvidence

The recent expansion of our Mental Health Network, now including over 1 million new patients, isn't just about numbers. It's about deepening our understanding of mental health patients and how their treatments work in the real world. Thanks to advanced AI and rich clinical data, we're pushing past surface-level insights and uncovering patterns that can lead to more personalized care. 📍Read the full announcement: https://okt.to/jaoswW Carl D. Marci, M.D. #MentalHealthAwarenessMonth #MentalHealth #AIHealthcare

NEW MEDIA 📣 PhenOM® foundation model trained on more than one billion years of patient health histories, representing the largest model of its kind to date. 📍Full press release: https://okt.to/BPJRGV #AI #MachineLearning #ISPORAnnual #ISPOR2025 #DigitalPhenotyping #News #Media

🧳 Are your bags packed for ISPOR? Review our checklist to make sure you don't forget anything! What are your conference essentials? Comfy shoes, extra room in your bag for swag, an extra phone charger? Tell us in the comments! ✅ Book a meeting here to complete your checklist 👉 https://okt.to/BbHePg ISPOR—The Professional Society for Health Economics and Outcomes Research Rich Gliklich Richard Jenkins Kathryn Starzyk Joseph Zabinski, Ph.D., M.E.M. Jessica Probst Chandrasekar Gopalakrishnan, MD, MPH David Giannino Bradley Snipes Todd Price Maria Demko #ISPOR2025 #HEOR #AI #MachineLearning #RealWorldEvidence

💡 Why do many rheumatoid arthritis (RA) patients still struggle despite advanced therapies? Most trials focus on early-stage patients, but real-world RA often means cycling through multiple treatments due to poor response or intolerance. 📊 At ISPOR 2025, Chandrasekar Gopalakrishnan, MD, MPH will share insights into this hard-to-treat group highlighting how real-world data can inform more precise, effective care. Stop by the poster or visit us at booth #1500 to learn more. ISPOR—The Professional Society for Health Economics and Outcomes Research #ISPORAnnual #ISPOR2025 #RheumatoidArthritis

🧠 How is AI evolving in the discovery and treatment of treatment-resistant depression? Collaborations with industry leaders led to published research on innovative TRD treatments, from pharmaceutical-grade psilocybin to esketamine. 📍Watch the full episode 👉 https://okt.to/TbhCzI Carl D. Marci, M.D. #AI #MentalHealth #TreatmentResistantDepression #TRD #Depression #Psilocybin #Esketamine